A detailed history of Parkside Financial Bank & Trust transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Parkside Financial Bank & Trust holds 2,655 shares of CPRX stock, worth $58,197. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,655
Previous 2,237 18.69%
Holding current value
$58,197
Previous $34,000 52.94%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$15.19 - $21.35 $6,349 - $8,924
418 Added 18.69%
2,655 $52,000
Q2 2024

Aug 05, 2024

SELL
$14.68 - $16.92 $6,429 - $7,410
-438 Reduced 16.37%
2,237 $34,000
Q1 2024

May 01, 2024

BUY
$13.18 - $17.11 $10,702 - $13,893
812 Added 43.59%
2,675 $42,000
Q4 2023

Feb 01, 2024

BUY
$11.78 - $17.29 $21,946 - $32,211
1,863 New
1,863 $31,000
Q3 2022

Nov 01, 2022

BUY
$7.06 - $15.52 $931 - $2,048
132 New
132 $2,000

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.25B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Parkside Financial Bank & Trust Portfolio

Follow Parkside Financial Bank & Trust and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parkside Financial Bank & Trust, based on Form 13F filings with the SEC.

News

Stay updated on Parkside Financial Bank & Trust with notifications on news.